These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 15592728)

  • 1. Escalating immunotherapy of multiple sclerosis--new aspects and practical application.
    Rieckmann P; Toyka KV; Bassetti C; Beer K; Beer S; Buettner U; Chofflon M; Götschi-Fuchs M; Hess K; Kappos L; Kesselring J; Goebels N; Ludin HP; Mattle H; Schluep M; Vaney C; Baumhackl U; Berger T; Deisenhammer F; Fazekas F; Freimüller M; Kollegger H; Kristoferitsch W; Lassmann H; Markut H; Strasser-Fuchs S; Vass K; Altenkirch H; Bamborschke S; Baum K; Benecke R; Brück W; Dommasch D; Elias WG; Gass A; Gehlen W; Haas J; Haferkamp G; Hanefeld F; Hartung HP; Heesen C; Heidenreich F; Heitmann R; Hemmer B; Hense T; Hohlfeld R; Janzen RW; Japp G; Jung S; Jügelt E; Koehler J; Kölmel W; König N; Lowitzsch K; Manegold U; Melms A; Mertin J; Oschmann P; Petereit HF; Pette M; Pöhlau D; Pohl D; Poser S; Sailer M; Schmidt S; Schock G; Schulz M; Schwarz S; Seidel D; Sommer N; Stangel M; Stark E; Steinbrecher A; Tumani H; Voltz R; Weber F; Weinrich W; Weissert R; Wiendl H; Wiethölter H; Wildemann U; Zettl UK; Zipp F; Zschenderlein R; Izquierdo G; Kirjazovas A; Packauskas L; Miller D; Koncan Vracko B; Millers A; Orologas A; Panellus M; Sindic CJ; Bratic M; Svraka A; Vella NR; Stelmasiak Z; Selmaj K; Bartosik-Psujik H; Mitosek-Szewczyk K; Belniak E; Mochecka A; Bayas A; Chan A; Flachenecker P; Gold R; Kallmann B; Leussink V; Mäurer M; Ruprecht K; Stoll G; Weilbach FX;
    J Neurol; 2004 Nov; 251(11):1329-39. PubMed ID: 15592728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000].
    Multiple Sklerose-Therapie-Konsensus Gruppe (MSTKG)
    Nervenarzt; 2001 Feb; 72(2):150-7. PubMed ID: 11256151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002].
    Rieckmann P; Toyka KV;
    Nervenarzt; 2002 Jun; 73(6):556-63. PubMed ID: 12243005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
    ; Rieckmann P
    Nervenarzt; 2006 Dec; 77(12):1506-18. PubMed ID: 17136556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Insight: interferon treatment in multiple sclerosis.
    Marrie RA; Rudick RA
    Nat Clin Pract Neurol; 2006 Jan; 2(1):34-44. PubMed ID: 16932519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in the treatment of multiple sclerosis?].
    Tackenberg B; Himmerich H; Wellek A; Oertel WH; Sommer N
    MMW Fortschr Med; 2007 May; 149 Suppl 2():51-5. PubMed ID: 17724968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
    Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
    J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
    Thrower BW
    Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunologic therapy for secondary and primary progressive multiple sclerosis].
    Ozawa K
    Nihon Rinsho; 2003 Aug; 61(8):1449-54. PubMed ID: 12962037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
    Rieckmann P; Toyka KV
    Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH
    Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
    Costello F; Stüve O; Weber MS; Zamvil SS; Frohman E
    Curr Opin Neurol; 2007 Jun; 20(3):281-5. PubMed ID: 17495621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
    Limmroth V; Malessa R; Zettl UK; Koehler J; Japp G; Haller P; Elias W; Obhof W; Viehöver A; Meier U; Brosig A; Hasford J; Putzki N; Kalski G; Wernsdörfer C;
    J Neurol; 2007 Jan; 254(1):67-77. PubMed ID: 17273808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1847-56. PubMed ID: 24986155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current therapeutic recommendations in multiple sclerosis.
    Berger T
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S37-45. PubMed ID: 20106347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.